It proves that it might not be your diet or exercise regimen, but your body that lacks the fundamental nutrition that is limiting your ability to lose weight
Skriver, C., Friis, S., Knudsen, L
#PharmD #clinicalpharmacy #Drugupdate #Obesitymanagement To view or add a comment, sign in Obesity Market is Expected to Witness Significant Growth by 2036 Due to Advancements in GLP-1 Therapies and Expanding Treatment Accessibility | DelveInsight: The obesity market is experiencing substantial transformation driven by the rising global obesity burden, growing awareness regarding obesity as a chronic disease, increasing adoption of GLP-1 receptor agonists, and the emergence of next-generation metabolic therapies
Tirzepatide as an alternative If semaglutide is not working for you or the regulatory landscape concerns you, tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown even greater weight loss in clinical trials
Using fat for energy can help you sustain long-duration workouts
10.4088/JCP.15r09984 J Clin Psychiatry